News for hackers. Stuff that matters.
Re:In its fight to keep drug prices high, big pharma leans o... by kaiju0 on Monday April 29, 2019 @10:24AM (#19778586)
You can't drive prices below a fundamental floor. Businesses stop operating without sufficient capitol. The pharma market is fighting hard to prevent becoming a commodity through legislated protections.
Re:In its fight to keep drug prices high, big pharma leans o... by rayiner on Monday April 29, 2019 @10:34AM (#19778682)
Sure, but the floor is not the efficient price level. The efficient price level balances the cost to the public with creating sufficient incentives for drug companies to invest in new drugs, thus maximizing long-term welfare. Driving prices to the floor doesn't do that.

Yes, drug companies don't want drugs to become a commodity. Nobody wants their products to become commodities. And we have to acknowledge that, at least maybe, the public shouldn't want drugs to become commodities (at least, not during the period of patent protection). Companies in commodity markets don't innovate. Look at where innovation is happening in the PC market. It's happening in companies that can make a big profit (Google, Apple), not companies that deal in commodities (Acer, HP).

But put that aside. Maybe the best thing is for drug companies to be like Acer rather than Apple. At the very least, honest reporting should acknowledge that we're talking about trade-offs. In the last few decades, new drugs and medical devices have revolutionized treatment for things like HIV, breast cancer, leukemia, Hepatitis C, prostate cancer, etc. The 5-year survival rate for prostate cancer has gone up from 68% in the 1970s, to 99% today. HIV went from being a death sentence to a chronic condition. Many leukemias went from being death sentences to being extremely treatable. That progress wouldn't be possible without the tens of billions of dollars a year that drug companies invest in R&D. We can choose to slow down that pace, in exchange for making the existing treatments more widely accessible. That's a totally acceptable choice. But it's deception to make it seem like it's not a choice.

Re:In its fight to keep drug prices high, big pharma leans o... by maxxxxx on Monday April 29, 2019 @10:59AM (#19778931)
How do you know that the higher drug prices in the US lead to more research instead of making executives and shareholders richer? You seem to imply that.

Everything aside at a minimum the US needs more transparency about pricing. The whole system with its coupons, rebates and middlemen seems to be set up to hide the real cost of drugs. Without transparency no real discussion can be had.

Re:In its fight to keep drug prices high, big pharma leans o... by refurb on Monday April 29, 2019 @12:30PM (#19779853)
We know because public drug manufacturers share that information. For the big companies, it's around 17-20% of revenues go into R&D.
Re:In its fight to keep drug prices high, big pharma leans o... by maxxxxx on Monday April 29, 2019 @02:09PM (#19780920)
They also have very good profit margins. Would they spend less on R&D if their margins got reduced? I am not talking about reducing profit to zero or below.
Re:In its fight to keep drug prices high, big pharma leans o... by refurb on Monday April 29, 2019 @02:42PM (#19781284)
Well, reduction in price means reduction in revenue, so I would assume they'd target the same 17-20% of a lower number.
Re:In its fight to keep drug prices high, big pharma leans o... by rayiner on Monday April 29, 2019 @11:05AM (#19778980)
> How do you know that the higher drug prices in the US lead to more research instead of making executives and shareholders richer? You seem to imply that.

Because I have an iPhone. It's made executives and shareholders at Apple quite rich. It's also, I'm confident, advanced the state-of-the-art far faster than if Apple had been a government-regulated utility of sorts, limited to a "fair" 10% profit margin.

If people were talking about the government exercising monopsony power to drive down the price of iPhones, I'd (a) except Apple to protest vigorously; and (b) worry about the impact on smartphone innovation. Drugs are no different. The fact that drugs are important to society doesn't change the basic mechanics of a capital- and talent-intensive industry.

Re:In its fight to keep drug prices high, big pharma leans o... by PretzelFisch on Monday April 29, 2019 @11:32AM (#19779274)
I have trouble with this iPhone analogy. The demand of an iPhone is fundamentally different then the demand for a drug. I don't think it's fair to compare price discovery of a luxury item to an item needed to survive or escape pain.
Re:In its fight to keep drug prices high, big pharma leans o... by maxxxxx on Monday April 29, 2019 @12:14PM (#19779679)
It would be pretty bad if the only phone options were iPhones or Pixels. For broad society we need cheap phones. Same for drugs or other medical treatments. First we need cheap options for all before we should worry about luxury treatments.
Re:In its fight to keep drug prices high, big pharma leans o... by AnthonyMouse on Monday April 29, 2019 @01:02PM (#19780188)
> First we need cheap options for all before we should worry about luxury treatments.

In this context the "luxury treatments" are drugs under patent and the "cheap options for all" are generics.

And then we can identify a specific problem -- we don't have enough generics because unless a drug is under patent, nobody has the incentive to pay to put it through FDA trials.

But you can't solve that by removing the profit from the "luxury drugs" -- that only makes it worse. Then nobody has the incentive to pay for FDA trials for anything.

The actual problem is that FDA trials are an unfunded mandate. Either they need to be made significantly less expensive somehow or the government needs to fund them itself so that more unpatented generics can actually get approved.

Re:In its fight to keep drug prices high, big pharma leans o... by PretzelFisch on Monday April 29, 2019 @03:57PM (#19782023)
My understanding is that the FDA trial is a trivial expense[1][2] in the whole drug development cycle. What I usually hear is that R&D that spans years to decades is what the pharma company wants to recoup during the patent phase.

https://www.jhsph.edu/news/news-releases/2018/cost-of-clinic... https://www.outsourcing-pharma.com/Article/2018/09/26/Clinic...

Re:In its fight to keep drug prices high, big pharma leans o... by AnthonyMouse on Tuesday April 30, 2019 @02:58AM (#19785713)
You're comparing the wrong numbers.

The trial costs are small compared to R&D costs, but that's only because R&D costs are very large. So it's millions of dollars compared to billions of dollars.

But generics don't have R&D costs, they already exist and are out of patent. Which correspondingly makes them much less profitable -- that's the whole point -- and then "millions of dollars" becomes a significant cost.

Moreover, it's a free rider problem, because once you pay for it for a generic drug, anyone can make it, but they didn't have to pay the millions of dollars for the trials so now they can undercut your price.

As a result everybody sits around waiting for somebody else to spend several million dollars for a trial instead of doing it themselves, which means that nobody does it.

Re:In its fight to keep drug prices high, big pharma leans o... by selimthegrim on Monday April 29, 2019 @11:33AM (#19779275)
None of that is an excuse for the shenanigans Avik Roy lists in this report, especially around orphan drugs

https://docs.house.gov/meetings/GO/GO00/20190129/108817/HHRG...

Re:In its fight to keep drug prices high, big pharma leans o... by maxxxxx on Monday April 29, 2019 @11:10AM (#19779036)
Perfect line of reasoning. Very convincing.

Let’s also stop negotiating any other government procurement. We will get some real cool fighter jets.